Education
About Us
Working with TipRanks
Follow Us
Zevra Therapeutics (ZVRA)
NASDAQ:ZVRA
Total Valuation
Zevra Therapeutics has a market cap or net worth of $370.69M. The enterprise value is $337.68M.
Market Cap$370.69M
Enterprise Value$337.68M
Share Statistics
Zevra Therapeutics has 54.12M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54.12M
Owened by Insiders0.63%
Owened by Instutions34.94%
Financial Efficiency
Zevra Therapeutics’s return on equity (ROE) is -2.66 and return on invested capital (ROIC) is -70.49%.
Return on Equity (ROE)-266.00%
Return on Assets (ROA)-59.23%
Return on Invested Capital (ROIC)-70.49%
Return on Capital Employed (ROCE)-60.39%
Revenue Per Employee$400,203.39
Profits Per Employee-$1,788,322.034
Employee Count59
Asset Turnover0.13
Inventory Turnover3.76
Valuation Ratios
The current PE Ratio of Zevra Therapeutics is -3.66. Zevra Therapeutics’s PEG ratio is -0.05.
PE Ratio-3.66
PS Ratio16.34
PB Ratio9.72
Price to Fair Value9.72
Price to FCF-5.54
Price to Operating Cash Flow-5.54
PEG Ratio-0.05
Income Statement
In the last 12 months, Zevra Therapeutics had revenue of $23.61M and earned -$105.51M in profits. Earnings per share was -$2.34.
Revenue$23.61M
Gross Profit$13.11M
Operating Income-$87.00M
Pretax Income-$90.14M
Net Income-$105.51M
EBITDA-76.40M
Earnings Per Share (EPS)-2.34
Cash Flow
In the last 12 months, operating cash flow was -$69.67M and capital expenditures $0.00, giving a free cash flow of -$69.67M billion.
Operating Cash Flow-$69.67M
Free Cash Flow-$69.67M
Free Cash Flow per Share-$1.29
Dividends & Yields
Zevra Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-18.06%
Earnings Yield-27.35%
Stock Price Statistics
Beta1.13
52-Week Price Change44.35%
50-Day Moving Average7.71
200-Day Moving Average7.67
Relative Strength Index (RSI)37.45
Average Volume (3m)531.82K
Important Dates
Zevra Therapeutics upcoming earnings date is May 8, 2025, TBA.
Last Earnings DateMar 11, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Zevra Therapeutics as a current ratio of 2.53, with Debt / Equity ratio of 1.52
Current Ratio2.53
Quick Ratio2.47
Debt to Market Cap0.16
Net Debt to EBITDA-0.35
Interest Coverage Ratio-11.84
Taxes
In the past 12 months, Zevra Therapeutics has paid $15.37M in taxes.
Income Tax$15.37M
Effective Tax Rate-17.05%
Enterprise Valuation
Zevra Therapeutics EV to EBITDA ratio is -5.40, with an EV/FCF ratio of -5.92.
EV to Sales17.46
EV to EBITDA-5.40
EV to Free Cash Flow-5.92
EV to Operating Cash Flow-5.92
Balance Sheet
Zevra Therapeutics has $69.50M in cash and marketable securities with $60.30M in debt, giving a net cash position of -$9.20M billion.
Cash & Marketable Securities$69.50M
Total Debt$60.30M
Net Cash-$9.20M
Net Cash Per Share-$0.17
Tangible Book Value Per Share-$0.74
Margins
Gross margin is 68.59%, with operating margin of -368.47%, and net profit margin of -446.85%.
Gross Margin68.59%
Operating Margin-368.47%
Pretax Margin-381.76%
Net Profit Margin-446.85%
EBITDA Margin-323.56%
EBIT Margin-350.62%
Analyst Forecast
The average price target for Zevra Therapeutics is $22.29, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$22.29
Price Target Upside223.04%
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast-14.02%
EPS Growth Forecast-72.44%